Chemocentryx, Inc.

Petrus Bekker

Israel Charo

Shichang Miao

Tom Schall

Jan Hillson

Jun Deng

The present disclosure provides methods for treating ANCA-associate vasculitis in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of avacopan: or a pharmaceutically acceptable salt thereof, such that the level of plasma complement factor Bb, C3a, or C5a does not significantly change in the human upon treatment.

Dosing and effect of C5a antagonist with ANCA-associated vasculitis

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.

Methods of treating pancreatic cancer

Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5R antagonist are provided.

Method of treating C3 glomerulopathy

Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.

Growing community of inventors

Mountain View, CA, United States of America

Petrus Bekker